2-[3-Methyl-5-[(5-methyl-2-phenylpyrazol-3-yl)methoxy]pyrazol-1-yl]butanoic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-[3-Methyl-5-[(5-methyl-2-phenylpyrazol-3-yl)methoxy]pyrazol-1-yl]butanoic acid
• 英文别名: 2-[3-methyl-5-[(5-methyl-2-phenylpyrazol-3-yl)methoxy]pyrazol-1-yl]butanoic acid
• 化学式: C₁₉H₂₂N₄O₃
• 分子量: 354.4
• InChiKey: GVNPYASEUCPXEB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  82.2
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] PYRAZOLE DERIVATIVES AND THEIR USES THEREOF<br/>[FR] DÉRIVÉS DE PYRAZOLE ET LEURS UTILISATIONS
  申请人：CANADIAN BLOOD SERVICES

  公开号：WO2014138979A1

  公开（公告）日：2014-09-18

  The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein U, R1, R2, R3 and Q are as defined herein. The disclosure also provides a method for treating or preventing a method for the prevention, treatment and/or alleviation of one or more autoimmune or alloimmune disease, pharmaceutical compositions and combination comprising a therapeutically effective amount of a compound, as defined herein.

  本公开涉及式(I)的化合物或其药用盐；其中U、R1、R2、R3和Q如本文所定义。本公开还提供了一种治疗或预防一种或多种自身免疫或异体免疫疾病的方法，包括药物组合和药物组合，其中含有按本文所定义的化合物的治疗有效量。
• PYRAZOLE DERIVATIVES AND THEIR USES THEREOF
  申请人：CANADIAN BLOOD SERVICES

  公开号：US20160022640A1

  公开（公告）日：2016-01-28

  The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein U, R1, R2, R3 and Q are as defined herein. The disclosure also provides a method for treating or preventing a method for the prevention, treatment and/or alleviation of one or more autoimmune or alloimmune disease, pharmaceutical compositions and combination comprising a therapeutically effective amount of a compound, as defined herein.

  本公开涉及式(I)的化合物或其药学上可接受的盐；其中U、R1、R2、R3和Q的定义如本文所述。本公开还提供了一种预防、治疗和/或缓解一种或多种自身免疫或异体免疫疾病的方法，以及包含所述化合物的治疗有效量的药物组合物和组合物。
• Pyrazole derivatives and their uses thereof
  申请人：CANADIAN BLOOD SERVICES

  公开号：US10130609B2

  公开（公告）日：2018-11-20

  The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein U, R1, R2, R3 and Q are as defined herein. The disclosure also provides a method for treating or preventing a method for the prevention, treatment and/or alleviation of one or more autoimmune or alloimmune disease, pharmaceutical compositions and combination comprising a therapeutically effective amount of a compound, as defined herein.

  本公开涉及式（I）化合物或其药学上可接受的盐；其中 U、R1、R2、R3 和 Q 如本文所定义。本公开还提供了一种治疗或预防一种或多种自身免疫或同种免疫疾病的方法、药物组合物和包含治疗有效量的本文所定义的化合物的组合物。